MedImmune boosts cancer R&D pipeline with potential $440M Spirogen buy

10/15/2013 | Reuters

AstraZeneca's MedImmune unit agreed to acquire Spirogen, a privately held biotech firm focused on antibody-drug conjugate technology, for $200 million upfront plus $240 million in milestone fees as part of efforts to strengthen its oncology research and development pipeline. The agreement includes a $20 million equity investment in Switzerland's ADC Therapeutics, which has a licensing deal with Spirogen. ADC's and Spirogen's technologies will allow MedImmune to "accelerate antibody-drug conjugates into the clinic," MedImmune Executive Vice President Bahija Jallal said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park